BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Company update

WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market

Related news

PTCTPTC Therapeutics, Inc.2026-11-02 13:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-10-30 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEOAbeona Therapeutics2026-11-02 12:46 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETONEton Pharmaceuticals2026-10-14 10:50 EST

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

MNPRMonopar2026-07-20 12:00 EST

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

MGTXMeiraGTx2026-09-23 12:00 EST

MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors

RHHBYRoche Holdings AG2026-09-23 05:00 EST

Change in Roche’s Board of Directors

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

ABEOAbeona Therapeutics2026-09-02 11:30 EST

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

ETONEton Pharmaceuticals2026-11-02 11:50 EST

Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-11-03 12:00 EST

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PTCTPTC Therapeutics, Inc.2026-11-02 13:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-10-30 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-10-29 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

Stock data

Close
65.67 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States